Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.79 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.79 |
| ▸ | RAB9A | P51151 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | CA1 | P00915 | 3/20 | 0.68 |
| ▸ | CA2 | P00918 | 3/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.68 |
| ▸ | CA9 | Q16790 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | CA5A | P35218 | 1/20 | 0.65 |
| ▸ | CA7 | P43166 | 1/20 | 0.65 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.64 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.64 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.64 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8802829 | 0.93 | CA12 (0.75) | LTA4HEPHX2RAB9AALDH1A1CA1 | |
| SCHEMBL4153733 | 0.90 | HPGD (0.79) | LTA4HEPHX2ALDH1A1CA1CA2 | |
| SCHEMBL8803161 | 0.86 | LTA4H (0.61) | LTA4HEPHX2RAB9AALDH1A1CA1 | |
| SCHEMBL4152627 | 0.85 | TRPV1 (0.78) | LTA4HEPHX2ALDH1A1CA1CA2 | |
| SCHEMBL4152553 | 0.85 | TRPV1 (0.78) | LTA4HEPHX2ALDH1A1CA1CA2 | |
| SCHEMBL8802955 | 0.84 | ALDH1A1 (0.69) | LTA4HEPHX2RAB9AALDH1A1CA1 | |
| SCHEMBL22664772 | 0.84 | CA1 (0.69) | LTA4HEPHX2ALDH1A1CA1CA2 | |
| SCHEMBL13332523 | 0.84 | EPHX2 (0.79) | LTA4HEPHX2RAB9AALDH1A1CA1 | |
| SCHEMBL6962982 | 0.84 | CA1 (0.69) | LTA4HEPHX2ALDH1A1CA1CA2 | |
| SCHEMBL28992212 | 0.83 | ALDH1A1 (1.00) | RAB9AALDH1A1CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661436-B1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2016-04-13 | — | — | EP | claimed |
| US-9233964-B2 | Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof | LEO PHARMA A/S (DK) | 2016-01-12 | — | — | US | claimed |
| US-20130345194-A1 | SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2013-12-26 | — | — | US | claimed |
| EP-2661436-A1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2013-11-13 | — | — | EP | claimed |
| WO-2012093169-A1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | WO | claimed |
| EP-0754041-A4 | NOVEL SUBSTITUTED TRYPTAMINES, PHENALKYLAMINES AND RELATED COMPOUNDS | INTERNEURON PHARMA (US) | 1997-11-19 | — | — | EP | claimed |
| EP-0754041-A1 | NOVEL SUBSTITUTED TRYPTAMINES, PHENALKYLAMINES AND RELATED COMPOUNDS | INTERNEURON PHARMACEUTICALS INCORPORATED (US) | 1997-01-22 | — | — | EP | claimed |
| WO-1995026723-A1 | NOVEL SUBSTITUTED TRYPTAMINES, PHENALKYLAMINES AND RELATED COMPOUNDS | INTERNEURON PHARMACEUTICALS, INC. (US) | 1995-10-12 | — | — | WO | claimed |
| EP-2661436-B1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2016-04-13 | — | — | EP | disclosed |
| US-9233964-B2 | Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof | LEO PHARMA A/S (DK) | 2016-01-12 | — | — | US | disclosed |
| US-20130345194-A1 | SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2013-12-26 | — | — | US | disclosed |
| EP-2661436-A1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2013-11-13 | — | — | EP | disclosed |
| WO-2012093169-A1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | WO | disclosed |
| EP-0754041-A4 | NOVEL SUBSTITUTED TRYPTAMINES, PHENALKYLAMINES AND RELATED COMPOUNDS | INTERNEURON PHARMA (US) | 1997-11-19 | — | — | EP | disclosed |
| EP-0754041-A1 | NOVEL SUBSTITUTED TRYPTAMINES, PHENALKYLAMINES AND RELATED COMPOUNDS | INTERNEURON PHARMACEUTICALS INCORPORATED (US) | 1997-01-22 | — | — | EP | disclosed |
| US-5580878-A | TREATING SLEEP DISORDERS | INTERNEURON PHARMACEUTICALS, INC. (US) | 1996-12-03 | — | — | US | disclosed |
| WO-1995026723-A1 | NOVEL SUBSTITUTED TRYPTAMINES, PHENALKYLAMINES AND RELATED COMPOUNDS | INTERNEURON PHARMACEUTICALS, INC. (US) | 1995-10-12 | — | — | WO | disclosed |
| US-5403851-A | Central nervous system and psychological disorders | INTERNEURON PHARMACEUTICALS, INC. (US) | 1995-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345194-A1 | SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS | JAK1, CNKSR1, TSHR | LTA4H 997/4885EPHX2 2821/4885RAB9A 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.